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Despite great progress in eliminating trachoma from the majority of worldwide districts, trachoma control seems to have stalled 
in some endemic districts. Can mathematical models help suggest the way forward? We review specific achievements of models in 
trachoma control in the past. Models showed that, even with incomplete coverage, mass drug administration could eliminate disease 
through a spillover effect, somewhat analogous to how incomplete vaccine campaigns can eliminate disease through herd protec-
tion. Models also suggest that elimination can always be achieved if enough people are treated often enough with an effective enough 
drug. Other models supported the idea that targeting ages at highest risk or continued improvements in hygiene and sanitation can 
contribute meaningfully to trachoma control. Models of intensive targeting of a core group may point the way to final eradication 
even in areas with substantial transmission and within-community heterogeneity.
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In 1999, the World Health Organization (WHO) declared a goal 
of reducing infectious trachoma to a level such that the potential 
for blindness resulting from trachomatous infections would no 
longer be a public health concern [1]. Specifically, WHO aimed 
to reduce the prevalence of the clinical signs of active trachoma 
(follicular trachoma [TF]) to <5% in all endemic districts 
worldwide. To achieve this, WHO proposed annual mass drug 
administration (MDA) worldwide to all endemic populations, 
targeting the ocular strains of Chlamydia trachomatis, the bac-
terium that causes trachoma [2]. Recommendations included 
3–5 annual mass antibiotic distributions to at least 80% of the 
population (a single dose of oral azithromycin, or 6 weeks of 
topical tetracycline for infants for whom oral azithromycin is 
not appropriate). In addition, facial hygiene and environmental 
(F&E) programs were recommended as a more sustainable way 
to reduce transmission [3]. These F&E initiatives were designed 
to encourage face washing and latrine building. Latrine build-
ing is intended to limit the preferred breeding ground of Musca 
sorbens, a presumptive mechanical vector of C. trachomatis [4].
Following nearly 2 decades of this strategy, the disease bur-
den of trachoma has been substantially reduced, with a reported 
2016 worldwide prevalence of 3 338 000 (Uncertainty Interval, 
2 439 000–4 492 000) [5]. Control programs have achieved 
remarkable success in the vast majority of districts worldwide [2]. 
Elimination has recently been successfully achieved in countries 
such as Morocco, Laos, Nepal, and Mexico [6–10]. However, some 
severely affected districts in Ethiopia have been treated for 10 years, 
and are still not close to reaching the WHO-specified threshold for 
declaring control and halting MDA. Mathematical models of dis-
ease transmission may have helped to provide some initial rationale 
for the frequency of MDA treatments in typical endemic regions 
that were successfully treated. Now mathematical and statistical 
models can be used to evaluate the impact of potential alternative 
interventions, treatment strategies for the remaining high-preva-
lence areas, and to forecast if and when control will be achieved 
worldwide. In this article, we review some of the ways mathemat-
ical and statistical models have been used over the past 2 decades 
to predict future prevalence and to explore the impact of different 
control interventions and predict disease prevalence.
FORECASTING OF PREVALENCE FOR 
PROGRAMMATIC DECISION MAKING
The programmatic outcome of an MDA campaign is typically 
evaluated using district-level prevalence surveys. Trachoma 
forecasts have been generated using a number of different 
approaches, including expert opinion, mechanistic models that 
include knowledge of disease transmission, and statistical mod-
els that include no specific knowledge of trachoma. One study 
demonstrated that both statistical and mechanistic models per-
form far better than expert opinion at forecasting trachoma 
prevalence 1 year in advance [11–13]. A separate analysis sug-
gested that forecasts generated by more complex mechanistic 
models do not perform better than forecasts generated by purely 
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statistical models [11]. However, even the statistical models are 
not that accurate at predicting individual district-level preva-
lence. This is in part because surveys are relatively infrequent, 
and in part because of considerable fluctuations in TF preva-
lence observed from year to year within a single district. This 
large apparent stochastic variation may mean that any improve-
ment in prediction offered by additional surveys may be limited.
On the other hand, forecasting changes in the distribution 
of district-level prevalence across a group of districts allows 
the model to leverage the information across multiple, highly 
stochastic processes, and has proven surprisingly successful 
(T.M.L., unpublished data).The distribution of the prevalence 
of trachoma across many districts can even be used to identify 
whether or not control is failing. Theoretical and empirical stud-
ies suggest that under subcritical conditions, the distribution of 
district-level prevalence should approach a geometric or expo-
nential distribution. In Figure  1, the distribution of infection 
from 75 communities in Tanzania is plotted in a histogram, and 
fitted well by an exponential distribution [14–16]. The fact that 
the distribution worldwide became approximately exponential 
in 2010 suggests that trachoma programs may have achieved 
control in most areas (T.M.L., unpublished data). Unfortunately, 
a closer examination reveals some outliers, unlikely to have 
come from an exponential distribution. The departure from 
exponential suggests that more will need to be done to control 
trachoma in these areas, which are for the most part in a few 
severely affected regions of Ethiopia (T.M.L., unpublished data). 
Here models could help provide insight into what intervention 
strategies could be implemented to help reach control.
Traditional definitions of hypo-, meso-, and hyperendemic 
regions based on baseline prevalence of TF have been useful 
to trachoma programs. However, because of the stochasticity 
mentioned above, it can be challenging to know how to inter-
pret a single community with high prevalence (eg, 20%) within 
an area with generally lower prevalence (eg, a mean of 8%). 
This would be expected given the relatively heavy tail of the 
exponential distribution, and would not in itself indicate pro-
gram failure or a hot spot that required more resources. Such a 
prevalence is completely consistent with expected fluctuations 
under subcritical conditions. On the other hand, in a region 
with multiple high-prevalence districts where the prevalence is 
not distributed exponentially, more resources may be needed to 
achieve control. One of the interesting questions is at what level 
(subnational, international) models are most effective at identi-
fying hotspots and in offering reassurance on program progress.
THE EFFECT OF EXISTING AND NEW STRATEGIES, 
INFORMED BY MODELING
Forecasts suggest that achievement of the global goals in all 
endemic districts will not be achieved by 2020, with several 
regions (essentially in Ethiopia) as clear outliers. Empirical 
evidence confirms that this is not solely due to a late initiation 
of treatment programs. The question then arises of what is the 
correct strategy in areas where the target is not being met. The 
simplest strategic response is simply to treat for more years. 
However, a plausible hypothesis is that transmission is simply 
so strong in these areas that current strategies are not sufficient 
to control disease. In these areas, mathematical models can 
suggest novel strategies that would then be testable in practice.
FACTORS THAT MAY UNDERMINE THE SUCCESS OF 
AN MDA PROGRAM
In some severely affected areas, 10 years of annual MDA has not 
come close to achieving the WHO threshold for control, with 
lingering infection within a community. Several hypotheses may 
explain the persistence of residual infection (Figure 2). Systematic 
noncompliance (a group of individuals who are systematically 
not accessing or seeking MDA treatment) may prevent success, if 
sustained transmission is achieved in this group [17] (Figure 2A). 
More data on noncompliance, from coverage surveys or other tools, 
could be useful in evaluating this possibility [17, 18]. The practical 
importance of noncompliance depends on which age group drives 
transmission. Modeling suggests that given the high prevalence of 
infection in 1- to 5-year-olds, intensive targeting of children could 
still in principle be sufficient to overcome a degree of noncompli-
ance in adults that was correlated over time [19] (Figure 2C).
Alternatively, individuals with high-bacterial-load infections 
may have a poorer chance of fully clearing the infection with a 
Figure  1. Distribution of community-level trachoma prevalence after multiple 
mass drug administrations. This figure shows the Tanzanian trachoma prevalence 
data as a histogram of district-level prevalences in the background, normalized so 
that the total area of the bars adds up to 100%. The best fit to the data was pro-
vided by an exponential distribution and is shown in black, along with the 95% 
confidence interval (CI) as gray shading. The other distributions shown (normal, 
Weibull, gamma, generalized gamma, beta, Gumbel, and a mixture of 2 exponen-
tial distributions) are multiple parameter distributions that include the exponential 
distribution as a special case. For fitting to the Tanzanian prevalence data, these 
more complex distributions clearly mimic the exponential with their fit within the 
95% CI of the exponential. This suggests that distributions more complicated than 
the exponential are not necessary to describe the data. Reprinted with permission 
from Rahman et al [15].
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single dose of antibiotic treatment [20] (Figure 2B). Modeling 
suggests that if this could be overcome by 2 treatments within 2 
weeks of each other, the number of “double-dose” annual cam-
paigns would be reduced [21]. This model assumed that the effi-
cacy of the 2 doses were not independent, with the second dose 
being more effective (further discussed below).
It is also possible that successive rounds of treatment may 
have selected for macrolide-resistant strains of chlamydia. This 
has not been found to be the case in the few studies that have 
assessed chlamydial resistance [22–24] (Figure 2D). Modeling 
has offered some insight into the regression of macrolide resist-
ance in Streptococcus pneumoniae after MDA has been discon-
tinued [25]. Macrolide resistance in C. trachomatis has not yet 
been found empirically, but the possibility of resistance could be 
modeled in the future. Alternatively, reintroduction from out-
side the community may be occurring (Figure 2E).
It is unlikely that any one of these possible mechanisms is the 
sole cause of the persistence of residual infection. Accordingly, 
efforts to intensify MDA and to conduct activities in addition to 
MDA may be needed.
INTENSIFICATION AND OPTIMIZATION OF 
ANTIBIOTIC CAMPAIGNS
Repeated MDA appears to confer indirect protection to 
untreated individuals, a spillover effect analogous to herd 
protection in vaccines [26]. Mathematical modeling has sug-
gested that infection can be eliminated from the most severely 
affected areas even without complete coverage, and this has 
been confirmed by longitudinal studies and community ran-
domized trials. In these models, the specific frequency and 
coverage of treatment is important to success [27, 28].
INCREASING THE FREQUENCY OF ANTIBIOTIC 
DISTRIBUTIONS
Transmission modeling analyses originally suggested that in 
hyperendemic areas, annual MDA with approximately 80% 
coverage might not be sufficient to eliminate infection, and that 
biannual treatment would be required in these areas (Figure 3) 
[27, 28]. Three clinical trials revealed that biannual treatment 
may eliminate infection somewhat more rapidly than annual 
treatment, although no significant differences could be found 
after 3–4 years of treatments [29, 30].
INCREASING ANTIBIOTIC COVERAGE
Mathematical models suggest that attaining a high level of cover-
age when implementing MDA is as important for elimination as 
the frequency of antibiotic distribution and efficacy of treatment 
[27]. However, programmatic MDA coverage is notoriously dif-
ficult to assess in practice. It is difficult to know how many indi-
viduals in a community were not identified in the pretreatment 
Figure 2. Schematic illustrating the potential reasons for failure of mass drug administration (MDA) within a community. A, Some infected individuals (in red) within the 
community miss treatment and act as a reservoir source of infection to the rest of the community. B, Infected individuals with high bacterial loads who are treated do not 
fully resolve their infection (in red) following 1 dose of treatment post-MDA and thus remain a source of infection to the community. C, Children make up the primary source 
of infections to the community and, following MDA, infection is most likely to return in children (red). D, Individuals infected in the community (red) are treated, but some 
individuals are infected with a resistant strain (green) and therefore treatment is ineffective; thus, individuals infected with the resistant strain can reseed infection into the 
community following MDA. E, Infected individuals in the community (red) are treated effectively following MDA; the community remains infection free for a period but infec-
tion is reintroduced from a neighboring community (blue).
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census, and hence accurately quantify the denominator popula-
tion that required treatment. A set of 3 community-randomized 
trials addressed antibiotic coverage in hypo- and mesoendemic 
areas (Partnership for Rapid Elimination of Trachoma [PRET]). 
Communities were randomized to 80% coverage (a level recom-
mended by the WHO and achievable in a single day) vs >90% 
coverage (only attained after 1–3 follow-up visits). Investigators 
were unable to demonstrate a statistically significant improve-
ment with enhanced coverage in any of the 3 country settings 
[31, 32]. Note that this did not study the range of lower coverages 
that may be present in some distribution programs.
OPTIMIZING THE TIMING OF ANTIBIOTIC 
DISTRIBUTION
Clinically active trachoma (TF) has been noted to vary over the 
course of the year, although definitive seasonality in infection 
has been more difficult to demonstrate [33]. If seasonal varia-
tion in transmission were pronounced, one mathematical mod-
eling study suggested that treatment 3 months before the high 
transmission season might be the most effective [34]. In areas 
where transmission is constant throughout the year, mathemat-
ical models have looked at the optimal timing of a second treat-
ment: either soon after the first (eg, 1–2 weeks after [21]), or 
6 months apart. If 2 treatments closer together result in the sec-
ond treatment being more effective, then short-interval double 
treatment results in higher clearance and reduced transmission 
[21]. If, however, treatment efficacy and coverage at each time 
point were independent, then it is straightforward to demon-
strate that the timing of the second treatment does not matter 
[35]. The Azithromycin in the Control of Trachoma (ACT) trial 
found remaining infection in the community after 3 weekly 
treatments with >95% coverage, suggesting that a second or 
third weekly dose may not result in a dramatic improvement 
in prevalence [36]. Individual randomized trials compar-
ing different regimens have had difficulty finding significant 
improvements [37, 38]. A  trial that assesses a second weekly 
dose is currently being set up (The Carter Center – Trachoma 
Elimination Study by Focused Antibiotics  [TCC-TESFA]), as is 
another evaluating 2 doses 2 weeks apart.
TARGETING CORE GROUPS
The largest risk factor for infection is age, with prevalence most 
commonly peaking in preschool children. Children are thought 
to have a longer duration of infection, and higher bacterial loads. 
If these highly infectious children could be removed from the 
transmission network, infection could eventually disappear in 
the community (Figures 2C and 4). One mathematical modeling 
study suggested that frequent treatment of children alone could 
eventually eliminate infection in the entire community, and 
short-term trial results are consistent with this [19]. A commu-
nity-randomized trial of treatment directed to children 4 times 
in a year in Ethiopia found that the prevalence of infection in 
untreated adults was reduced nearly in half by the end of the year 
[26], and quarterly treatment of children was superior to annual 
treatment of everyone in one trial. Biannual treatment of chil-
dren aged 0–12 years in Niger also reduced infection in adults, 
and had similar efficacy to treating all ages once per year [39].
Treatment of clinically active children and their households 
has had modest success in community-randomized trials in 
Nepal and Ethiopia, although an analysis including some trans-
mission modeling suggested that it may not be cost-effective 
due to the cost of identifying actively affected children [40–42] 
(National Institutes of Health [NIH], Trachoma Amelioration 
in Northern Amhara II [TANA II] study).
TREATMENT OF A CORE GROUP REMAINING 
INFECTED DESPITE MANY ROUNDS OF MDA
Individuals in the community who are infected at an endemic 
equilibrium may represent a possible core group for the trans-
mission of infection. In a sense, communities in the most severely 
affected areas have reached a new “steady” state, or equilibrium, 
where prevalence remains constant at the new lower level after 
5–10  years of MDA. While this level may be far lower than 
the pretreatment prevalence, this new equilibrium can still be 
higher than control targets of <5% TF. Epidemiological studies 
have shown that those currently infected with ocular chlamydia 
are the most likely to be infected later, even if after being cleared 
of their original infection [43–45]. Thus, the group that remains 
infected may form a residual core group—if annual distribu-
tions were continued and this group was effectively taken out 
of the transmission network, mathematical models suggest that 
Figure 3. Frequency of mass drug administration necessary to achieve elimin-
ation. Projections are based on the assumptions that treatment is administered 
once, annually, or biannually; coverage is 80%; and antibiotic efficacy in an indi-
vidual is 95%. Projections follow logistic growth determined by the following equa-
tion: baseline prevalence / (1 + C e−[rate of return][time]), where C is a constant that is fit 
by the empirical data. Adapted from Melese et al [28].
Figure 4. The necessary frequency of treatments that will ensure the eventual 
elimination of active trachoma if only individuals under a certain age are treated. 
Although annual treatment may well eliminate disease if everyone in the popu-
lation is treated, biannual treatment may be necessary if treatment is limited to 
children 1–10  years old. Results of the uncertainty analysis: black curve, 50th 
percentile; gray curves, 25th and 75th percentiles (based on data from Malawi). 
Adapted from Lietman et al [27].
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infection could be completely eliminated [27]. If these groups 
could be identified, quarterly treatment of this group with oral 
azithromycin could effectively remove them from the transmis-
sion network. Although resource intensive, this strategy may be 
what is required in a small number of severely affected com-
munities where infection continues to persist. Two versions 
of the strategy targeting a residual core group are at different 
stages of clinical trial testing (NIH studies Sanitation, Water, 
and Instruction in Face-washing for Trachoma [SWIFT] and 
Kebele Elimination of Trachoma For Ocular Health [KETFO]), 
although larger-scale studies may be required.
INTENSIFY THE HYGIENE AND SANITATION 
COMPONENTS
Trachoma disappeared from some areas of the world before 
the discovery of antibiotics, which has led many to believe that 
improved environmental conditions may help to reduce trans-
mission of infection [46]. Mathematical modeling has demon-
strated that if reductions in the transmission potential of the 
pathogen could be achieved by improving water supply, sanita-
tion, and hygiene (WASH), then control could be more achiev-
able and sustainable in certain locations [21]. Unfortunately, no 
additional benefit from F&E interventions has ever been proven. 
While WASH indicators clearly correlate with a lower prevalence 
of trachoma at the individual and community level [47], no clin-
ical trial has demonstrated that any nonantibiotic intervention 
actually reduces chlamydial infection [3, 48]. A  large commu-
nity-randomized trial is now being conducted to assess whether 
intensive F&E reduces infection in a severely affected area (NIH 
National Eye Institute, SWIFT), and other trials are also being 
planned to test the hypothesis. If the trials can prove that any 
particular F&E intervention actually reduces infection, this 
could be incorporated into future models [21, 49].
CONCLUSIONS
In regions where the WHO trachoma strategy is currently not 
controlling the disease, mathematical models can be used to 
suggest, evaluate, and investigate the possible impact of alter-
native strategies. These can then be tested in a clinical trials set-
ting in a falsifiable manner. Increased dosing at the individual 
or the community level and the impact of F&E continue to be 
assessed in large randomized trials. If an effect is demonstrated, 
it might facilitate elimination in currently difficult-to-treat 
areas. Intensive targeting of a residual core group that remains 
infected following annual MDA is currently being tested in se-
verely affected regions of Ethiopia. While transmission models 
may help inform the design of new strategies for these regions, 
a number of biological uncertainties underlying these models 
remain, and more detailed data would probably be required to 
distinguish between them [50]. Advances in mathematical and 
statistical modeling are allowing forecasting of the district-level 
prevalence of trachoma to be improved. While statistical fore-
casting suggests that control worldwide in 2020 is extremely un-
likely, success in the next decade is indeed feasible, and forecasts 
can help with planning and with keeping expectations realistic.
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